Here are four things to know about the company’s stock:
• Barclays currently has an overweight rating on the stock.
• K2M has a one-year low of $12.31 and a one-year high of $23.63.
• The stock’s 50-day moving average is $19 and its 200-day moving average is $17.
• The company’s market cap is $859.92 million.
More articles on devices:
Amedica to present CASCADE clinical results
Dr. Jacob Rosenstein performs 1st spinal fusion with Arena-C HA — 5 thing to know
1st reverse shoulder replacement using Zimmer device successfully completed in U.S.
At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.
